Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | LITAF | Q99732 | 1/20 | 0.40 |
| ▸ | FNTA | P49354 | 1/20 | 0.39 |
| ▸ | FNTB | P49356 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776965 | 1.00 | STS (0.45) | STSMEN1KMT2AGPR119MAPT | |
| SCHEMBL22792005 | 0.86 | STS (0.44) | STSMEN1KMT2AGPR119MAPT | |
| SCHEMBL22776493 | 0.86 | GPR119 (0.45) | GPR119HPGDS | |
| SCHEMBL16040735 | 0.83 | GPR119 (0.40) | STSMEN1KMT2AGPR119MAPT | |
| SCHEMBL25258371 | 0.82 | GPR119 (0.44) | STSMEN1KMT2AGPR119MAPT | |
| SCHEMBL25858237 | 0.80 | USP30 (0.41) | GPR119MAPT | |
| SCHEMBL16049455 | 0.79 | MAP4K4 (0.44) | STSGPR119MAPTPOLBHPGDS | |
| SCHEMBL23607102 | 0.78 | MAPK8 (0.48) | STSMEN1KMT2AGPR119MAPT | |
| SCHEMBL20839829 | 0.77 | GPR119 (0.44) | GPR119MAPT | |
| SCHEMBL31605050 | 0.77 | STS (0.42) | STSMEN1KMT2AGPR119MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324880-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCA1, SMARCE1, PBRM1 | STS 2865/4885MEN1 2050/4885KMT2A 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.